News summary

Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026

Source: PR Newswire • Published: 16 Nov 2026, 12:30

Summarized by Masters of Longevity from PR Newswire.

Preclinical peptides reduced body weight and food intake and extended drug exposure.

Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026
Key Takeaways
  • Lipidated peptides showed extended half-life in rodent and dog models.
  • Selective peptides produced significant weight-loss and reduced food intake.
  • PL2001 was selected for clinical development with IND activities ongoing.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.